文献速递糖尿病肥胖与代谢综合征

二甲双胍治疗青春期肥胖青少年两年未保护β细胞功能

Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该双盲安慰剂对照试验纳入44名青春期早期(Tanner 2-3期)肥胖且血糖正常的健康青少年,评估二甲双胍治疗至Tanner 5期对胰岛素敏感性和β细胞功能的影响。结果显示二甲双胍改善BMI z评分、体脂百分比和腰围,但未显著改善胰岛素敏感性、急性胰岛素反应或处置指数。

要点

  • 二甲双胍治疗两年改善肥胖青少年BMI z评分、体脂和腰围。
  • 二甲双胍未改善胰岛素敏感性或β细胞功能指标。
  • 青春期早期高处置指数可能预测后期处置指数下降。

核心结论

  • 青春期肥胖青少年二甲双胍治疗两年改善BMI和体脂,但不改善胰岛素敏感性或β细胞功能。

研究设计与样本

  • 双盲安慰剂对照试验,纳入44名青春期早期(Tanner 2-3期)肥胖且血糖正常的健康青少年,治疗至Tanner 5期。

主要发现

  • T5时二甲双胍组BMI z评分变化-0.44 ± 0.16(P=0.02),体脂百分比变化-3.4 ± 1.2%(P=0.06),腰围变化-11.3 ± 3.2 cm(P=0.003)。
  • T5时胰岛素敏感性变化0.85 ± 0.87 × 10-4/min-1/μIU/mL(P=0.34),急性胰岛素反应变化-259 ± 386 μIU/mL(P=0.51),处置指数变化508 ± 802 × 10-4/min-1(P=0.53)。
  • 基线高处置指数预测处置指数纵向下降。

临床怎么用

  • 二甲双胍可用于改善青春期肥胖青少年的BMI和体脂,但不应期望其保护β细胞功能。

局限性

  • 样本量较小(n=44),需进一步研究开发保护β细胞功能的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Youth-onset type 2 diabetes is a disease of pubertal onset, associated with additional burden of pubertal insulin resistance on the β-cell. OBJECTIVE: Evaluate the impact of metformin treatment during puberty, a critical window of cardiometabolic change, on insulin sensitivity (Si) and compensatory β-cell response in youth with obesity. SETTING: Pediatric academic hospital clinical translational research center. PARTICIPANTS: Healthy youth in early puberty [Tanner stage (T) 2-3] with normoglycemia and obesity (n = 44). INTERVENTION: Double-blinded placebo-control trial of metformin during puberty (until T5). MAIN OUTCOME MEASURES: Insulin sensitivity (Si), insulin response [acute insulin response to glucose (AIRg)], and disposition index (DI), estimated from frequently sampled intravenous glucose tolerance testing; body fat (dual X-ray absorptiometry); and other laboratory parameters, collected at baseline, T4, and T5. Placebo-subtracted treatment effect was calculated using linear mixed models. RESULTS: At T5, metformin treatment, adjusting for sex, race, and baseline value, was associated with improved BMI z-score (-0.44 ± 0.16, P = 0.02), percentage body fat (%body fat; -3.4 ± 1.2%, P = 0.06), and waist circumference (-11.3 ± 3.2cm, P = 0.003). There were no significant treatment effects at T5 on Si or secretion: Si (0.85 ± 0.87 × 10-4/min-1/μIU/mL, P = 0.34), AIRg (-259 ± 386 μIU/mL, P = 0.51), or DI (508 ± 802 × 10-4/min-1, P = 0.53). High baseline DI predicted longitudinal decline in DI. CONCLUSIONS: Two years of metformin treatment in obese youth during puberty improved BMI and body fat, but not Si or β-cell function. Of note, high DI in early puberty may be predictive of later decline in DI. Further studies are needed to develop strategies for preservation of β-cell function in youth at risk for type 2 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kelsey MM, Hilkin A, Pyle L, et al. Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity. J Clin Endocrinol Metab. 2021. PMID: 33728428. doi:10.1210/clinem/dgab170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。